Overview

This trial is active, not recruiting.

Conditions hepatitis c, chronic, fibrosis
Treatments peg-interferon alpha 2b (drug), ribavirin (drug), prazosin (drug)
Phase phase 2
Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Start date September 2004
Trial size 112 participants
Trial identifier NCT00148837, 2004-001326-24, ANRSHC17 Prazor

Summary

Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose treatment

Primary Outcomes

Measure
Proportion of patients presenting a decrease of fibrosis as measured on the liver biopsy and considered as clinically interesting (decrease of fibrosis pre- and post-therapeutic (W96) measures of at least 10 percent)
time frame:

Secondary Outcomes

Measure
Metavir scoring system; immunostaining of alpha-smooth muscle actin; indirect markers of fibrosis (Fibrotest) at W96
time frame:
Sustained virological response: undetectable HCV RNA at W96
time frame:
Sustained biochemical response: ALT level at W96
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Chronic viral hepatitis C, genotype 1 or 4 - Fibrosis F3 or F3-F4, assessed by the scoring Metavir system - Initial treatment against HCV Exclusion Criteria: - Psychiatric pathology - Alcool consummation - Pregnancy or plan of pregnancy - Breastfeeding

Additional Information

Official title Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Principal investigator de Ledinghen Victor, MD, PhD
Description Treatment of hepatitis C with interferon and ribavirin has a virological effect. Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. In vitro studies of prazosin suggest an effect against hepatic fibrosis, but the clinical effect of prazosin on the hepatic fibrosis induced by hepatitis C infection is unknown. The purpose of this multicentric national study is to compare the effects among the hepatic fibrosis of peg-interferon alpha 2b and ribavirin with prazosin or not (placebo). 112 patients with a viral hepatitis C, genotype 1 or 4, and severe fibrosis, will be randomly assigned to one of two treatment groups: peg-interferon alpha 2b and ribavirin, with prazosin or with placebo. Peg-interferon alpha 2b will be administered once a week (1.5 micro g per kg) during 48 weeks, ribavirin 1,000 to 1,200 mg per day (according to weight) during 48 weeks, prazosin/placebo 5 mg (2 pills) per day during 96 weeks. Evaluation will be done at 96 weeks. The primary end-point is the proportion of patients presenting a decrease of fibrosis. Secondary end-points are other criteria of histological response, virological response, biochemical response.
Trial information was received from ClinicalTrials.gov and was last updated in February 2008.
Information provided to ClinicalTrials.gov by French National Agency for Research on AIDS and Viral Hepatitis.